Sanofi Expects EUR100 Million After-Tax Profit Hit From Dengvaxia Update
November 29 2017 - 1:01PM
Dow Jones News
By Alberto Delclaux
Sanofi SA (SAN.FR) said Wednesday that it expects a negative
impact of 100 million euros ($118.8 million) on its fourth-quarter
after-tax profit after updating information on its dengue vaccine
Dengvaxia.
The company will ask regulators to update the product label on
Dengvaxia after long-term trial data found differences in vaccine
performance based on prior dengue infection.
The trial results found that for people who hadn't previously
been infected by dengue, vaccination would make the disease worse
should they subsequently become infected. For those who had
previously contracted dengue, data showed that Dengvaxia provided
persistent protection.
Sanofi will propose that health authorities update the
prescribing information to request that health-care professionals
assess the likelihood of prior infection in an individual before
vaccinating. For those who have not been previously infected by
dengue virus, vaccination should not be recommended, it added.
The company will record a charge in its fourth-quarter results
reflecting depreciation of inventories, as well as accelerated
depreciation of some assets, it said. Sanofi said it nevertheless
confirms its guidance for "broadly stable" after-tax earnings per
share in 2017.
Write to Alberto Delclaux at alberto.delclaux@dowjones.com
(END) Dow Jones Newswires
November 29, 2017 12:46 ET (17:46 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2023 to Sep 2024